Moolec's Nasdaq Fate Balances on December 18 Delisting Vote

Moolec Science SA's stock price has plummeted below $0.03 in pre-market trading, marking a 7.59% decline over the past 24 hours, as the company faces a critical regulatory crossroads with Nasdaq. The biotech firm, listed under the ticker MLEC, received a determination letter from the exchange on November 14, 2025, stating that its share price had remained below the $1 minimum for 30 consecutive business days, triggering compliance concerns under Nasdaq Listing Rule 5550(a)(2).

The development comes as a significant challenge for Moolec, which has submitted an appeal to a Nasdaq Hearings Panel seeking a 180-day compliance window. The panel's decision is slated for December 18, 2025, during which the company's shares will continue trading uninterrupted. In its appeal, Moolec has indicated a willingness to consider a reverse stock split-a common strategy to boost share prices-if deemed beneficial to shareholders. The company emphasized its commitment to resolving the issue and regaining compliance, though it noted that the Nasdaq determination does not impact its ongoing business operations or SEC reporting obligations.

The stock's decline underscores broader challenges for Moolec, which leverages molecular farming and precision fermentation to develop sustainable protein solutions. Despite a robust intellectual property portfolio-comprising over 118 granted and pending patents-the company has yet to achieve sustained profitability. Its diversified pipeline includes alternative proteins, bioactive compounds, and agricultural inputs, but commercial scalability remains a hurdle. The current regulatory scrutiny adds pressure as the firm navigates a competitive market and works to translate its technological innovations into financial viability.

Nasdaq's enforcement of minimum pricing rules reflects ongoing efforts to maintain listing standards, particularly for smaller-cap companies. While Moolec's appeal buys time, the outcome will hinge on whether the panel grants the compliance extension. If denied, the company may face delisting unless it implements immediate corrective measures. Analysts note that a reverse stock split, while potentially boosting the share price, could also signal financial distress and dilute existing shareholders.

As the deadline approaches, investors and stakeholders will closely watch Moolec's next steps. The company's ability to stabilize its stock price and demonstrate progress in its compliance plan will be critical to maintaining market confidence. For now, the focus remains on the December 18 hearing, which could determine the trajectory of Moolec's Nasdaq listing-and its broader growth strategy.